Europeiska unionen - svenska - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se avsnitt 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Europeiska unionen - svenska - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alk-abelló a/s - allergen, bigift - injektionsvätska, suspension - 100 000 sq-e/ml - allergen, bigift 100000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mg adjuvans - insekter

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alk-abelló a/s - allergen, bigift - injektionsvätska, suspension - styrkeserie - allergen, bigift 1000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mikrog adjuvans; allergen, bigift 100 sq-u aktiv substans; aluminiumoxid, hydratiserad 0,04 mg adjuvans; aluminiumoxid, hydratiserad 4 mg adjuvans; allergen, bigift 10000 sq-u aktiv substans; aluminiumoxid, hydratiserad 0,4 mg adjuvans; allergen, bigift 100000 sq-u aktiv substans - insekter

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alk-abelló a/s - allergen, getinggift - injektionsvätska, suspension - 100 000 sq-e/ml - aluminiumoxid, hydratiserad 4 mg adjuvans; allergen, getinggift 100000 sq-u aktiv substans - insekter

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

alk-abelló a/s - allergen, getinggift - injektionsvätska, suspension - styrkeserie - allergen, getinggift 100000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mg adjuvans; aluminiumoxid, hydratiserad 0,4 mg adjuvans; allergen, getinggift 10000 sq-u aktiv substans; aluminiumoxid, hydratiserad 0,04 mg adjuvans; allergen, getinggift 1000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mikrog adjuvans; allergen, getinggift 100 sq-u aktiv substans - insekter

Europeiska unionen - svenska - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastiska medel - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

otsuka novel products gmbh - delamanid - tuberkulos, multidrug-resistent - medel mot mykobakterier - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 och 5. hänsyn bör tas till officiella riktlinjer för lämplig användning av antibakteriella medel.

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - immunförsvaret sera och immunglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se avsnitt 4. 4 och 5.

Europeiska unionen - svenska - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastiska medel - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.